Completed PHASE3 INTERVENTIONAL 7-arm NCT00025259

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease

Sponsor: Children's Oncology Group

Conditions Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma Childhood Mixed Cellularity Classical Hodgkin Lymphoma Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma Childhood Nodular Sclerosis Classical Hodgkin Lymphoma Stage I Childhood Hodgkin Lymphoma Stage II Childhood Hodgkin Lymphoma Stage III Childhood Hodgkin Lymphoma Stage IV Childhood Hodgkin Lymphoma

Interventions Bleomycin Sulfate Cisplatin Cyclophosphamide Cytarabine Dexamethasone Doxorubicin Hydrochloride Etoposide Filgrastim Involved-Field Radiation Therapy Prednisone Vincristine Sulfate Liposome

Updated 8 times since 2017 Last updated: Mar 15, 2017 Started: Sep 30, 2002 Primary completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00025259, this PHASE3 trial focuses on Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma and Childhood Mixed Cellularity Classical Hodgkin Lymphoma and remains completed. Sponsored by Children's Oncology Group, it has been updated 8 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

May 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — May 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Oncology Group
National Cancer Institute (NCI)

Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , Albuquerque, United States , Amarillo, United States , Ann Arbor, United States , Asheville, United States , Augusta, United States , Aurora, United States , Austin, United States , Baltimore, United States and 137 more locations